De novo biosynthesis of eriocitrin in Saccharomyces cerevisiae through deep learning-guided enzyme screening and systematic metabolic engineering
Synthetic and Systems Biotechnology · 2026-09 · 13 · 143-153
DOI: 10.1016/j.synbio.2026.01.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synthetic and Systems Biotechnology, 2026-09. Verfasst von Qiyuan Lu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Longping Agricultural College, Hunan University, Changsha, 410125, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Jiangsu Agricultural Science and Technology Innovation Fund.
Abstract (Originalsprache)
Eriocitrin, a flavanone-7-O-disaccharide known for its antioxidant and anti-inflammatory properties, holds considerable promise for use in functional foods and pharmaceuticals. However, its large-scale production is constrained by the limitations of conventional plant extraction, including low abundance of active compounds and seasonal variability. Here, we established a de novo biosynthetic pathway for eriocitrin from glucose in engineered Saccharomyces cerevisiae through combinatorial metabolic engineering. First, to verify the feasibility of glycosylation in the eriocitrin synthesis process, two highly efficient flavonoid-7-O-glucosyltransferases were identified using an integrated bioinformatics and deep learning approach. Subsequently, through the reconstruction of the UDP-rhamnose synthesis pathway and enhancement of the key glycosylation precursor UDP-glucose supply, an eriocitrin titer of 147.9 mg/L was achieved following supplementation with 300 mg/L eriodictyol. To further achieve the de novo synthesis of eriocitrin, an eriodictyol-producing strain was developed by screening the optimal F3'H/CPR pair, engineering promoters, and pathway integration, achieving an eriodictyol titer of 237.8 mg/L. Finally, combining the eriodictyol-producing chassis strain with the previously optimized glycosylation module enabled the de novo production of eriocitrin, reaching a titer of 30.5 mg/L. This work demonstrates a proof-of-concept for microbial production of flavonoid disaccharides, providing a foundation for a sustainable and scalable supply of eriocitrin.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Longping Agricultural College, Hunan University, Changsha, 410125, China.
- DongTing Laboratory, Hunan Institute of Agricultural Product Processing and Quality Safety, Hunan Academy of Agricultural Sciences, Changsha, 410125, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Jiangsu Agricultural Science and Technology Innovation Fund
Zitieren
APA
Lu, Q., Tan, X., Zhang, S., Wang, Y., Zhao, Y., Liu, J., Hu, F., Zuo, S., Chen, J., Fan, L., Ding, S., Xiao, Z., & Shan, Y. (2026). De novo biosynthesis of eriocitrin in Saccharomyces cerevisiae through deep learning-guided enzyme screening and systematic metabolic engineering. Synthetic and Systems Biotechnology, 13, 143-153. https://doi.org/10.1016/j.synbio.2026.01.019
Vancouver
Lu Q, Tan X, Zhang S, Wang Y, Zhao Y, Liu J, et al. De novo biosynthesis of eriocitrin in Saccharomyces cerevisiae through deep learning-guided enzyme screening and systematic metabolic engineering. Synthetic and Systems Biotechnology. 2026;13:143-153. doi:10.1016/j.synbio.2026.01.019
BibTeX
@article{Lu2026,
author = {Lu, Qiyuan and Tan, Xinjia and Zhang, Siqi and Wang, Yongtong and Zhao, Yifei and Liu, Juan and Hu, Fanglin and Zuo, Shasha and Chen, Jiaxu and Fan, Liusha and Ding, Shenghua and Xiao, Zhiqiang and Shan, Yang},
title = {De novo biosynthesis of eriocitrin in Saccharomyces cerevisiae through deep learning-guided enzyme screening and systematic metabolic engineering},
journal = {Synthetic and Systems Biotechnology},
year = {2026},
volume = {13},
pages = {143--153},
doi = {10.1016/j.synbio.2026.01.019}
}
EUVIMED